Evaluation of the efficacy of romosozumab for hemodialysis patients with hemodialysis

Evaluation of the efficacy of romosozumab for hemodialysis patients with hemodialysis - Evaluation of the efficacy of romosozumab for hemodialysis patients with hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039889

Enrollment

Registered

2020-03-31

Start date

2020-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Injections of romosozumab (at a dose of 210 mg) monthly for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 20 years or older with chronic hemodialysis patients with osteoporosis who have not sufficiently improved osteoporosis even after standard treatment for 6 months or more.

Exclusion criteria

Exclusion criteria: 1)Patients who are not receiving standard treatment for osteoporosis 2)Persons who are contraindicated in taking evenity or denosumab 3)Patients who have taken romosozumab or denosumab within 6 months 4)Hypocalcemia 5)Patients with severe liver dysfunction, heart dyfunction, malignant tumor 6)Patients who are judged by the investigator not to be eligible for drug administration.

Design outcomes

Primary

Measure	Time frame
Bone mineral density at 12 months after treatment	—

Countries

Japan

Contacts

Public ContactTomohiro Saito

Showa University School of Medicine Department of Medicine, Division of Nephrology

saitou1986@med.showa-u.ac.jp0337848000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026